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Summary
Gut peptides, exemplified by glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are
secreted in a nutrient-dependent manner and stimulate glucose-dependent insulin secretion. Both GIP and GLP-1 also pro-
mote b cell proliferation and inhibit apoptosis, leading to expansion of b cell mass. GLP-1, but not GIP, controls glycemia via
additional actions on glucose sensors, inhibition of gastric emptying, food intake and glucagon secretion. Furthermore,
GLP-1, unlike GIP, potently stimulates insulin secretion and reduces blood glucose in human subjects with type 2 diabetes.
This article summarizes current concepts of incretin action and highlights the potential therapeutic utility of GLP-1 receptor
agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes.A complex set of physiological responses is activated following
meal intake, providing neural and endocrine signals regulating
the digestion, absorption, and assimilation of ingested nutrients
(Figures 1 and 2). Following the development and utilization of
insulin radioimmunoassays for the study of glucose tolerance,
a series of studies demonstrated that plasma levels of insulin
were significantly greater followingoral administrationof glucose
relative to levels achieved following intravenous glucose chal-
lenge in normal human subjects. This gut-associated potentia-
tion of insulin secretion was attributable to one or more humoral
or neural factors, termed incretins, that potentiated insulin secre-
tion following enteral nutrient ingestion. Consistent with these
observations, administration of intestinal extracts stimulated
insulin secretion in dogs. The identity of the putative incretin fac-
tor(s) remained elusive until the purification and characterization
of the first incretin, glucose-dependent insulinotropic polypep-
tide (GIP) in the 1970s. Although GIP was shown to be a potent
stimulator of glucose-dependent insulin secretion, removal of
GIP from gut extracts via immunoabsorption did not eliminate
the incretin effect, providing evidence for the existence of addi-
tional peptides with incretin-like activity (Ebert et al., 1983).
Over a decade later, a second peptide with incretin activity
was identified following cloning and characterization of the
proglucagon gene. Glucagon-like peptide-1 (GLP-1), a peptide
coencoded carboxyterminal to glucagon in the proglucagon
gene, was shown to potently stimulate glucose-dependent insu-
lin secretion in both preclinical and humanstudies (Drucker et al.,
1987; Kreymann et al., 1987). This Review summarizes the phys-
iological actions of these hormones (Figure 1) and the therapeu-
tic potential of enhancing incretin action for the treatment of type
2 diabetes.
Incretin synthesis and secretion
GIP is a 42 amino acid peptide produced predominantly in duo-
denal K cells in the proximal small intestine. GIP has also been
localized to the central nervous system, where it may play a
role in control of cell survival (Nyberg et al., 2005). The predom-
inant stimulus for GIP secretion is nutrient intake; circulatingCELL METABOLISM 3, 153–165, MARCH 2006 ª2006 ELSEVIER INC.levels of GIP are low in the fasted state and rise within minutes
of food ingestion. As GIP contains an alanine at position 2, it is
an excellent substrate for dipeptidyl peptidase-4, an essential
enzyme regulating the degradation of both GIP and GLP-1. Full-
length GIP(1–42) is rapidly converted to bioinactive GIP(3–42)
within minutes of secretion from the gut K cell (Kieffer et al.,
1995). Hence, circulating immunoreactive GIP represents amix-
ture of active GIP(1–42) and inactive GIP(3–42), and experimen-
tal analysis of levels of circulating GIP requires discrimination
between the intact versus the cleaved peptides. In contrast,
GLP-1 is produced in enteroendocrine cells in the distal small
bowel and colon. Plasma levels of GLP-1 also rise rapidly within
minutesof food intake, hence it seems likely that bothneural and/
or endocrine factors promoteGLP-1 secretion fromdistal L cells,
well before digested nutrients traverse the small bowel to make
direct contact with enteroendocrine L cells. Although gastrin-
releasing peptide and GIP stimulate GLP-1 secretion in some
species, the identity of the endocrine or neural factors promoting
rapid release of GLP-1 in humans remains unclear. Similarly,
neurotransmitters such as VIP and PACAP likely mediate insuli-
notropic action following meal ingestion, but function as neuro-
transmitters, rather than circulating incretins.
Proglucagon is processed to glicentin, oxyntomodulin, GLP-1,
and GLP-2 in gut L cells, via processing that requires prohormone
convertase-1. Bioactive GLP-1 is generated from GLP-1(1–37)
and exists as two equipotent circulating molecular forms, GLP-
1(7–37) and GLP-1(7–36)amide. GLP-1(7–36)amide represents
the majority of circulating active GLP-1 in human plasma (Orskov
et al., 1994). Both forms of GLP-1, likeGIP, also contain an alanine
at position 2 and are rapidly degraded by DPP-4 to GLP-1(9–
36)amide or GLP-1(9–37) following release from gut L cells. Al-
though a separate receptor for GLP-1(9–36)amide has not yet
been identified,evidencesupportsa role for thispeptide inglucose
clearance or regulation of cardiovascular function. The degra-
dation of GLP-1 is remarkably rapid such that a substantial pro-
portion of immunoreactive GLP-1 in the portal and systemic circu-
lation has already been cleaved by DPP-4. In addition to the
importance of DPP-4 for inactivation of GLP-1 andGIP, both pep-
tides are also rapidly cleared from the circulation via the kidney.DOI 10.1016/j.cmet.2006.01.004 153
R E V I E WFigure 1. GLP-1 actions in peripheral tissues
GLP-1 acts directly on the endocrine pancreas, heart, stomach, and brain, whereas actions on liver and muscle are indirect.Molecular mechanisms of incretin action
on the endocrine pancreas
The humanGLP-1 receptor (GLP-1R) is a 463 amino acid hepta-
helical G protein-coupled receptor widely expressed in pancre-
atic islets, kidney, lung, heart, andmultiple regions of the periph-
eral and central nervous system. Within islets, the GLP-1R is
predominantly localized to b cells, although GLP-1R expression
on islet a and d cells has also been reported. Although numerous
studies allege the functional existence of a secondGLP-1 recep-
tor, only a single GLP-1R coupled to glucose homeostasis has
yet been identified. Engagement of theGLP-1R stimulates cyclic
AMP formation and activation of downstreampathways coupled
to protein kinase A and cAMP-regulated guanine nucleotide ex-
change factors (Holz, 2004). GLP-1R agonists promote cyclic
AMP response element binding protein (CREB) phosphorylation
and also regulate CREB activity through glucose-dependent sti-
mulation of the cytoplasmic to nuclear translocation of TORC2,
a CREB coactivator. GLP-1R activation is also coupled to in-
creased intracellular calcium, inhibition of voltage-dependent
K+ (Kv) currents and activation of immediate early gene expres-
sion through effects on Erk1/2, protein kinase C, and phosphati-
dylinositol 3-kinase (PI3K).
The human GIP receptor exists as two isoforms, 466 and 493
amino acids, expressed in islet b cells, adipose tissue, heart, and
brain. GIP receptor activation is also coupled to adenylyl cyclase
activation, an increase in intracellular Ca2+, and arachidonic acid
efflux. GIP stimulates growth factor-dependent pathways in-
cluding MAPK (extracellular signal-regulated kinases 1 and 2154[ERK 1/2]), PI3K, and protein kinase B (Akt). Both the GLP-1
and GIP receptors undergo rapid and reversible homologous
and heterologous desensitization in vitro, however GIP, but not
GLP-1 appears to induce rapid receptor desensitization in vivo.
The genes encoding the human GLP-1 or GIP receptors have
not been linked to enhanced genetic susceptibility for diabetes.
Both GLP-1 and GIP stimulate glucose-dependent insulin se-
cretion via activation of their specific G protein-coupled recep-
tors expressed directly on islet b cells. The precise mechanisms
by which GIP and GLP-1 stimulate insulin secretion only at ele-
vated levels of plasma glucose remain unclear. Both incretins
stimulate cyclic AMP formation and protein kinase A activation
(Figure 3), although inhibitors of PKAdo not completely abrogate
the effects of incretins on insulin secretion. The PKA-indepen-
dent stimulation of insulin secretion by incretins has been attrib-
uted to guanine nucleotide exchange factors (GEFs), particularly
cyclic AMP-GEFII (Epac2) (Ozaki et al., 2000), and reduction of
GEFII expression substantially attenuates the effects of GLP-1
on insulin secretion (Kashima et al., 2001). A role for sulfonylurea
receptor (SUR) subunits in modulating GLP-1R-dependent KATP
channel closure has been described. Although GLP-1 and GIP
stimulate cyclic AMP formation in SUR12/2 islets, the insulino-
tropic actions of both incretins are markedly diminished in
SUR12/2 mice, likely due to defective coupling of cyclic AMP to
pathways regulating insulin exocytosis (Nakazaki et al., 2002;
Shiota et al., 2002). These findings are consistent with a modula-
tory role forSUR1 in thecyclicAMP-dependent regulationofCa2+-
induced exocytosis. In contrast, GLP-1, but not GIP, retains insu-
linotropic actions in Kir6.22/2 mice (Miki et al., 2005), providingCELL METABOLISM : MARCH 2006
R E V I E WFigure 2. Contrasting roles of GLP-1 and GIP on glucose homeostasis
GLP-1 secreted into the portal vein activates a portal glucose sensor that signals, via vagal afferents, the central nervous system and in turn, vagal efferents enhance insulin
secretion. Both GLP-1 and GIP also directly activate insulin secretion via binding to their distinct receptors on islet b cells.further evidence for divergence of incretin signaling pathways
and complexity of KATP channel subunit action in the b cell.
Unlike other secretagogues acting primarily through the KATP
channel, GLP-1 also replenishes insulin stores via stimulation
of proinsulin gene expression (Drucker et al., 1987). These ef-
fects are mediated via increases in proinsulin gene transcription
and mRNA stability through cyclic AMP-dependent PKA-inde-
pendent mechanisms. The transcription factor Pdx-1 is an im-
portant target for the actions of GLP-1 on insulin gene expres-
sion. GLP-1 increases Pdx-1 expression through enhancement
of Pdx-1 gene expression, and augmentation of Pdx-1 binding
to the insulin gene promoter (Wang et al., 1999). Reduction or
elimination of Pdx-1 expression is associated with reduction of
GLP-1 receptor expression and loss of GLP-1 action on the
b cell, in studies using cell lines or islets in vitro or in mice with
a b cell-specific inactivation of the Pdx-1 gene in vivo (Li et al.,
2005b; Wang et al., 2005).
GLP-1 also lowers glucose via inhibition of glucagon secretion
from islet a cells. The inhibition of glucagon secretion may be
direct via GLP-1 receptors expressed on a cells or indirect via
stimulation of insulin and somatostatin secretion. Mice with
b cell-specific inactivation of the pdx-1 gene exhibit defective
suppression of glucagon secretion following exendin-4 adminis-
tration, illustrating the importance of the b cell in the inhibition of
a cell secretory activity (Li et al., 2005b). Of direct clinical rele-
vance, the GLP-1R-dependent suppression of glucagon secre-
tion is regulated in a glucose-dependentmanner, thereby reduc-
ing the risk of hypoglycemia by relieving inhibition of the a cellCELL METABOLISM : MARCH 2006once glucose falls to the normal or hypoglycemia range (Degn
et al., 2004; Nauck et al., 2002).
Activation of GLP-1R signaling in rodent and human pancre-
atic exocrine cell lines initiates a program of differentiation
toward a more endocrine-like phenotype, in association with
increased expression of genes such as Pdx-1, glucokinase,
andGLUT-2 (Zhouet al., 2002).GLP-1Ragonistsmay inducedif-
ferentiation via induction of transcription factors such as Foxa2,
leading to increased Pdx-1 gene transcription. Pdx-1 appears
critical for transducing the effects of GLP-1R agonists on exo-
crine cell differentiation, as PANC-1 cells fail to differentiate in
the absence of Pdx-1 expression (Hui et al., 2001). GLP-1 has
also been shown to promote the differentiation of progenitors
derived from human islets into functioning b cells.
GLP-1R agonists also enhance b cell proliferation in studies
employing islet cell lines, normal islets, or rodents.Unlike the glu-
cose-dependent actions of GLP-1 on insulin secretion, GLP-1R
agonists enhance b cell proliferation and expand b cell mass
even in normoglycemic rodents (Edvell and Lindstrom, 1999;
Kim et al., 2003; Xu et al., 1999). Remarkably, a transient 5 day
neonatal treatment with GLP-1 or the GLP-1R agonist exendin-
4 inWistar rats exposed to a single doseof streptozotocin at birth
results in improved b cell mass, findings persistent even in
2-month-old animals (Tourrel et al., 2001). Similarly, transient
treatment of rats subjected to a period of intrauterine growth
retardation with exendin-4 following birth leads to expansion of
b cell mass in rats and prevents the development of diabetes
(Stoffers et al., 2003).155
R E V I E WFigure 3. GLP-1 receptor signal transduction pathways in the pancreatic b cell
GLP-1 receptor activation leads to insulin release via stimulation of exocytotic pathways and recruits signaling mechanisms leading to promotion of cell proliferation and
survival.GLP-1R agonists promote expansion of islet mass in associa-
tion with increased Pdx-1 expression in diabetic mice (Stoffers
et al., 2000) and in rats following partial pancreatectomy (Xu
et al., 1999). The proliferative and antiapoptotic actions of
GLP-1R agonists on the b cell are dependent on the expression
of Pdx-1. Impairment of Pdx-1 expression is associated with re-
duced expression of theGLP-1 receptor and decreased respon-
sivity to exendin-4 in vitro (Wang et al., 2005). Furthermore, mice
with b cell-specific inactivation of the Pdx-1 gene exhibit an
increased rate of b cell apoptosis, and exendin-4 fails to stimu-
late b cell proliferation or inhibit apoptosis in Pdx-12/2 islets
(Li et al., 2005b).
GLP-1R agonists also promote preservation and expansion of
b cell mass through inhibition of apoptotic pathways (Figure 3).
GLP-1 reduces caspase-3 expression and nuclear fragmentation
in islets of Zucker diabetic rats, and exendin-4 markedly attenu-
ates b cell apoptosis in db/db mice (Wang and Brubaker, 2002)
or in wild-type mice following exposure to streptozotocin (Li
et al., 2003). Given the potential importance of reactive oxygen156species as mediators of b cell cytoxocity, it is noteworthy that
GLP-1R activation reduces apoptosis in MIN6 cells exposed to
hydrogen peroxide in a cAMP- and PI3K-dependent manner, in
associationwith increased expression ofBcl-2 andBcl-xL and re-
duced cleavage of poly-(ADP-ribose)-polymerase (Hui et al.,
2003). Similarly, both GLP-1 and exendin-4 reduced palmitate-
mediated caspase-3 activation and apoptosis in a PKA-depen-
dentmanner in Rinm5F cells (Kwonet al., 2003). GLP-1-mediated
stimulation of cyclic AMP leads to enhanced expression ofCREB,
induction of IRS2, and potentiation of Akt activation (Jhala et al.,
2003). Conversely, abrogation of Akt activity using a dominant
negative Akt cDNA eliminated the prosurvival actions of exen-
din-4 in murine islet cells following exposure to cytokines in vitro
(Li et al., 2005a). GLP-1R activation also reduces ER stress inmu-
rine islets in vivo, reduces eIF2a phosphorylation, promotes in-
duction of ATF4, CHOP, and sXBP-1, and modulates the PERK
arm of the endoplasmic reticulum stress pathway in islet b cells.
GLP-1R agonists stimulate proliferation of b cells in part
through transactivation of the epidermal growth factor receptorCELL METABOLISM : MARCH 2006
R E V I E W(EGFR) (Buteauetal., 2003) (Figure3).GLP-1also inhibits the tran-
scriptional regulator Foxo1 in islet cells through phosphorylation-
dependent nuclear exclusion inanEGFR-dependentmanner, and
exendin-4 failed to stimulate b cell replication or expansion of islet
mass in transgenic mice with constitutive expression of Foxo1 in
the nucleus. Similarly, a functional IRS-2 signaling pathway is
essential for the exendin-4-dependent stimulation of Akt phos-
phorylation, Pdx-1 expression and b cell growth, but not for stim-
ulation of insulin secretion in murine islets (Park et al., 2005). The
proliferative and antiapoptotic actions of GLP-1 have raised the
possibility thatGLP-1maybeuseful for preservationor expansion
of isletmass in thesettingof islet transplantation. Althoughadmin-
istration of exendin-4 to mice following islet transplantation did
not produce improved glucose control, pretreatment of cultured
islets with exendin-4 prior to transplantation improved reversal
of hyperglycemia following transplantation (King et al., 2005).
The actions of GLP-1 on insulin secretion, b cell proliferation,
and survival have also been demonstrated in experiments with
human islets.GLP-1 inducedmembranedepolarization, inhibition
of whole-cell KATP currents, and potentiation of Ca
2+-dependent
exocytosis in isolated human b cells (Gromada et al., 1998).
Both GLP-1 and GIP accelerated Ca2+ influx through voltage-
dependent (L-type) Ca2+ channels and potentiated exocytosis at
a site distal to a rise in the cytoplasmic Ca2+ concentration (Gro-
mada et al., 1998). Similarly, GLP-1 produced a rapid increase
in intracellular calcium that was inhibited by a cAMP antagonist
([Rp]-cAMPS), an L-type Ca2+ channel antagonist (nimodipine),
an antagonist of the endoplasmic reticulumCa2+ ATPase (thapsi-
gargin), or by ryanodine (Holz et al., 1999). GLP-1 promotes a
growth-factor-dependent pathway in human islets in vitro via
activation of Rap and B-Raf, in associationwith increased activity
of extracellular signal-regulated kinase (ERK), Akt, and PI3K (Park
et al., 2005; Trumper et al., 2005). GLP-1 improved glucose-
stimulated insulin secretion, increasedBcl-2 and reducedBaxex-
pression, and enhanced survival of human islet cells in 72 hr cul-
tures (Farilla et al., 2003). GLP-1 also reduced apoptosis in human
islets inducedby elevated concentrations of glucose or palmitate,
alone or in combination (Buteau et al., 2004). Hence, the available
evidence suggests that GLP-1R signaling pathways (Figure 3) are
highly conserved in rodent versus human islets.
GIP has also been shown to exert proliferative and antiapo-
ptotic actions on islet b cells. GIP improved survival of rat INS-1
cells after serum or glucose deprivation or following exposure
to wortmannin or streptozotocin (Ehses et al., 2003). The prosur-
vival actions of GIP were associated with reduced caspase-3
activation andwere dependent on the p38MAPK pathway. Sim-
ilarly, GIP promotes cell survival in INS-1(832/13) cells subjected
to glucolipotoxicity and in murine islets via downregulation of
Bax transcription, due to GIP-mediated reduction in nuclear
Foxo1 expression (Kim et al., 2005). Moreover, a 2 week infusion
of GIP also downregulated Bax and increased Bcl-2 expression
in pancreatic b cells of ZDF rats (Kim et al., 2005). Although the
insulinotropic actions of GIP are diminished in hyperglycemic ro-
dents due in part to reduced levels of GIP receptor expression
(Lynn et al., 2001), much less is known about the chronic effects
of diabetes on preservation of GIP-dependent pathways linked
to cell growth and survival.
Extrapancreatic actions of incretins
An important determinant of GLP-1 action on control of post-
prandial glucose is deceleration of the rate of gastric emptying,CELL METABOLISM : MARCH 2006which occurs within minutes of pharmacological exogenous
GLP-1R agonist administration. The mechanism(s) by which
GLP-1 inhibits gastric emptying appear complex and involve
communication with the central and peripheral nervous system
(Figure 2). Gastric distension increases the expression of c-Fos
in brainstem neurons producing GLP-1 (Vrang et al., 2003) and
vagal afferent denervation abolishes the effects of GLP-1 on
gastric emptying in the rat (Imeryuz et al., 1997). Although small
peptides such as GLP-1 and exendin-4 are capable of rapidly
crossing the blood-brain barrier and directly access the central
nervous system (CNS), highermolecular weight GLP-1R agonists
that do not cross the blood-brain barrier are still capable of inhib-
iting gastric emptying and food intake (Baggio et al., 2004). These
findings emphasize the importance of ascending vagal afferents
for GLP-1R-dependent control of gastrointestinal motility. Antag-
onism of the inhibitory effects of GLP-1 on gastric emptying via
the prokinetic agent erythromycin results in a much greater
GLP-1-stimulated rise in plasma insulin and a loss of the suppres-
sion of glucagon secretion following meal ingestion (Meier et al.,
2005). GLP-1 receptors are also directly expressed in the stom-
ach on gastric parietal cells, where GLP-1 may directly regulate
gastric acid secretion (Schmidtler et al., 1994), however the ef-
fects of GLP-1 on gastric acid secretion were abolished in vago-
tomized human subjects (Wettergren et al., 1997). Hence, consid-
erable evidence supports the importance of vagal innervation for
GLP-1R-dependent control of gastric secretion and motility.
Both intracerebroventricular (icv) and peripheral administra-
tion of GLP-1R agonists inhibits food intake in rodents (Tang-
Christensen et al., 1996; Turton et al., 1996), and GLP-1 recep-
tors have been localized to hypothalamic nuclei important for
the regulation of satiety. Repeated icv administration of GLP-1
in rats produces weight loss, whereas icv administration of the
GLP-1R antagonist exendin(9–39) for 3 days produced weight
gain, and exendin(9–39) administered together with NPY poten-
tiated the increases in food intake andweight gain observedwith
NPY alone (Meeran et al., 1999). Chronic peripheral administra-
tion of GLP-1R agonists is consistently associated with reduc-
tions in food intake andweight loss in preclinical studies (Szayna
et al., 2000; Young et al., 1999). In contrast, GIP has little effect
on gastric emptying or the control of food intake.
GLP-1 also elicits a potent aversive effect in rodents, including
development of a conditioned taste aversion (CTA) (Thiele et al.,
1997), which may contribute to the anorectic actions of this
peptide. Furthermore, central administration of aGLP-1 receptor
antagonist attenuates the development of a CTA in response to
lithium chloride administration in rats, suggesting that endoge-
nous GLP-1R circuits are important for transduction of aversive
signals (Rinaman, 1999; Seeley et al., 2000; Thiele et al., 1998).
Treatment of neonatal rats with monosodium glutamate abol-
ishes the anorectic response to GLP-1, implicating a role for
the arcuate nucleus and circumventricular organs in the trans-
duction of the GLP-1 anorectic response (Tang-Christensen
et al., 1998). Similarly, the sites of GLP-1 action for generation
of a CTA versus anorexia have been elucidated via region-spe-
cific administration of GLP-1 agonists and antagonists in rats.
Administration of GLP-1 into either the lateral or fourth ventricle
produced comparable inhibition of food intake whereas only
lateral ventricular GLP-1 produced a conditioned taste aversion.
Conversely, administration of GLP-1 directly into the central
nucleus of the amygdala (CeA) produced a strong CTA without
generation of anorexia (Kinzig et al., 2002). These observations157
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actions of GLP-1 on aversive and anorectic pathways.
GLP-1 actions and peripheral glucose sensors
GLP-1 may also mediate its effects on glucose control indepen-
dent of insulin secretion through activation of peripheral sensors
linked to enhanced glucose disposal (Figure 2). Intraportal GLP-
1, but not GIP, augments the firing of hepatic vagal afferents
andpancreatic vagal efferents, ascending nerves communicating
signals to the brain and then through neural relays, to the pan-
creas, respectively (Nakabayashi et al., 1996). Similarly, the gan-
glionic blocker chlorisondamine inhibited the stimulatory effects
of portal GLP-1 on insulin release in rats, evidence implicating
a GLP-1R-dependent neural signal emanating from the portal
circulation (Balkan and Li, 2000). Although theGLP-1Rantagonist
exendin(9–39) did not inhibit the GLP-1-dependent activation
of vagal afferent firing in rats, exendin(9–39) eliminated the en-
hanced portal-mediated glucose clearance in mice, and GLP-
1R2/2mice do not exhibit enhanced glucose clearance after por-
tal glucose infusion (Burcelin et al., 2001). The importance of
portalGLP-1 for enhancedglucose clearancehas alsobeendem-
onstrated indogs.More recent studieshave suggested thatGLP-1
action in the brain promotes a reduction in insulin-stimulated
glucose uptake in muscle and favors enhanced liver glycogen
storage, signals communicated via neural pathways (Knauf
et al., 2005). Hence, the coordinate release of digested nutrients
andGLP-1 into theportal circulationmayaugment glucoseclear-
ance independent of the peripheral actions of circulating GLP-1.
GLP-1 actions in the heart
GLP-1 receptors are expressed in the rodent and human heart,
however the specific cellular localization of GLP-1R expression
within the heart has not yet been reported. In mice and rats,
GLP-1R agonists rapidly increase heart rate and blood pressure
(Barragan et al., 1994). The effect of intravenously administered
GLP-1 on arterial blood pressure and heart rate is eliminated by
the icv or intravenous administration of the antagonist exendin-
(9–39) (Barragan et al., 1999), consistent with a role for central
GLP-1R+ neurons in control of the cardiovascular response.
Furthermore, exendin-4 and GLP-1 activate c-Fos expression
in the adrenal medulla and in neurons in autonomic control sites
in the rat brain, and rapidly activate tyrosine hydroxylase tran-
scription in brainstem catecholamine neurons (Yamamoto
et al., 2002). GLP-1 increases cyclic AMP in isolated cardiomyo-
cyteswithout affecting contractility, hence the precise role of the
GLP-1R in cardiac cells remains incompletely understood (Vila
Petroff et al., 2001). In contrast, although GLP-1R agonists tran-
siently increase levels of cortisol in human subjects, no signifi-
cant changes in catecholamines, heart rate, or blood pressure
have been detected following acute administration of GLP-1R
agonists. A role for GLP-1 in the improvement of endothelial
function in patientswith type 2 diabetes has also been described
(Nystrom et al., 2004).
GLP-1 also improves myocardial function and cardiac output
(Figure 1) in experimentalmodels of cardiac injury or heart failure.
GLP-1 increased cardiac output, and reduced left ventricular
end diastolic pressure, in association with improved myocardial
insulin sensitivity and myocardial glucose uptake in dogs with
rapid pacing-induced congestive heart failure (Nikolaidis et al.,1582004a). Consistent with the cytoprotective actions of GLP-1 in
the endocrine pancreas, GLP-1 reduced infarct size in the iso-
lated perfused rat heart and in animal models of myocardial
ischemia (Bose et al., 2005; Nikolaidis et al., 2005a). The cardio-
protective actions of GLP-1 were abolished in the presence of
the cyclic AMP inhibitor Rp-cAMP, the PI3kinase inhibitor
LY294002, and the p42/44 mitogen-activated protein kinase in-
hibitor (MAPK) UO126 (Bose et al., 2005). Remarkably, GLP-1
also exerts beneficial effects on cardiac function in human sub-
jects following myocardial infarction and angioplasty. A 72 hr
infusion of GLP-1 in patients with acute myocardial infarction
and an ejection fraction less than 40% resulted in significantly
improved left ventricular ejection fraction and improved regional
and global wall motion scores, in associationwith a trend toward
earlier hospital discharge (Nikolaidis et al., 2004b). Whether the
beneficial effects of GLP-1 on the injured heart are primarily
direct via activation of cardiac GLP-1R signaling or indirect via
GLP-1R-dependent improvement in levels of glucose and insulin
requires further investigation. Furthermore, the demonstration
that GLP-1(9–36)amide improves myocardial glucose uptake
and ventricular contractility in dogs with pacing-induced dilated
cardiomyopathy suggests that someof the cardiovascular effects
of native GLP-1 may be mediated by a distinct GLP-1(9–36)
receptor (Nikolaidis et al., 2005b).
Physiological actions of endogenous GLP-1 and GIP
The importance of endogenous incretin action has been exam-
ined in studies employing peptide antagonists or in incretin
receptor knockout mice. The GLP-1R antagonist exendin(9–39)
binds to the GLP-1 receptor and has been used to demonstrate
the essential physiological role of endogenous GLP-1 for glu-
cose homeostasis in mice, rats and human subjects. Exen-
din(9–39) increases both fasting and postprandial glycemia
and reduces meal-stimulated levels of circulating insulin in ro-
dents, baboons, and human subjects (Baggio et al., 2000;
D’Alessio et al., 1996; Edwards et al., 1999; Kolligs et al., 1995;
Schirra et al., 2005). Exendin(9–39) also increases plasma levels
of glucagon inhumansubjects at normal or elevated levels of glu-
cose, consistent with the importance of endogenous GLP-1 as
a tonic inhibitor of glucagon secretion (Schirra et al., 1998). En-
dogenousGLP-1 is also essential for control of gastric emptying,
as exendin(9–39) enhanced gastric emptying following oral glu-
cose administration in rats (Imeryuz et al., 1997) and increased
antro-pyloro-duodenal motility in human subjects (Schirra
et al., 2005). The importance of GIP for glucose homeostasis
has been studied using peptide antagonists of GIP action or anti-
sera directed against the GIP receptor in rats and mice. These
experiments have demonstrated a predominant role for GIP in
the regulation of postprandial glucose clearance. In contrast to
studies with GLP-1, endogenous GIP does not appear to be
important for control of fasting glucose (Baggio et al., 2000;
Lewis et al., 2000; Tseng et al., 1996).
Disruption of the murine GLP-1R results in mild fasting hyper-
glycemia and impaired glucose tolerance in association with
defective insulin secretion following both oral and intraperitoneal
glucose challenge (Scrocchi et al., 1996, 1998b). In contrast, de-
spite the importance of exogenous GLP-1 for satiety and weight
loss, food intake and bodyweight are normal inGLP-1R2/2mice
on a normal or high-fat diet (Scrocchi et al., 1996; Scrocchi and
Drucker, 1998). Similarly, plasma levels of glucagon andCELL METABOLISM : MARCH 2006
R E V I E Wregulation of gastric emptying are not perturbed in the absence
of GLP-1R signaling (Baggio et al., 2004; Pederson et al., 1998;
Scrocchi et al., 1998b). GLP-1R2/2mice also exhibit phenotypes
in the central nervous system and heart. Although the reproduc-
tive function of the hypothalamic-pituitary axis is not significantly
perturbed following loss of GLP-1R action, GLP-1R2/2 mice ex-
hibit increased corticosterone responses to stress (MacLusky
et al., 2000). Furthermore, GLP-1R2/2 mice exhibit learning def-
icits and enhanced sensitivity to seizure activity and neuronal in-
jury following kainate administration, and these phenotypes were
corrected following restoration of GLP-1R expression using ad-
enoviral gene transfer (During et al., 2003). GLP-1R2/2mice also
exhibit defects in cardiac structure and myocardial contractility,
implying an essential role for GLP-1R signaling in the control of
cardiac development and/or function (Gros et al., 2003).
Targeted disruption of themurineGIPR produces amodest im-
pairment of oral glucose tolerance, with no abnormalities in fast-
ing glucose or intraperitoneal glucose clearance (Miyawaki et al.,
1999). Although food intake and body weight are normal in
GIPR2/2 mice on a regular diet, these mice exhibit resistance to
diet-induced obesity and reduced expansion of adipocyte mass
following several months of high-fat feeding (Miyawaki et al.,
2002, 1999). Furthermore, ob:ob:GIPR2/2 mice exhibit reduced
weight gain, decreased adiposity, enhanced thermogenesis,
and improved glucose homeostasis, implicating a role for GIPR
signaling in the control of adipocytemass and energy expenditure
(Miyawaki et al., 2002). Consistent with these findings, although
chronic administration of GIP receptor antagonists impairs glu-
cose tolerance in normalmice (Irwin et al., 2004), daily administra-
tion of theGIP antagonist (Pro3)-GIP to ob/obmicemarkedly low-
ered levels of glucose and insulin in association with increased
insulin sensitivity (Gault et al., 2005). Furthermore, (Pro3)-GIP
treatment attenuated the development of islet hypertrophy and
b cell hyperplasia. Hence, transient or genetic disruption of GIP
action in rodents ameliorates diabetes, likely through modulation
of fat accumulation in adipocytes, thereby leading todiminution of
insulin resistance (Gault et al., 2005). Although the importance of
GIP action in the CNS is not well understood, both GIP and the
GIPR are expressed in the brain, and GIPR2/2 mice exhibit re-
duced numbers of cells in the hippocampal dentate gyrus, impli-
catinga role forGIP in neurogenesis (Nyberget al., 2005).GIPalso
exerts anabolic and proliferative actions in bone, and GIPR2/2
mice exhibit reduced bone mass, abnormal bone architecture,
and altered bone turnover (Xie et al., 2005), however GIP does
not modulate bone resorption in human subjects.
Surprisingly, genetic disruption of both GLP-1 and GIP recep-
tors in a single DIRKOmouse produces only a modest perturba-
tion in glucose homeostasis (Hansotia et al., 2004; Preitner et al.,
2004), raising the possibility that the b cell is capable of adapting
to the absence of GIP and GLP-1 action without adverse conse-
quences for glucose homeostasis. Moreover, the phenotype of
the Glp-1R2/2 and DIRKOmice may also reflect the importance
of disruptedGLP-1Rsignaling in thebrain, as emerging evidence
implicates an important role for central GLP-1R-dependent
pathways in the control of glucose disposal and energy homeo-
stasis (Knauf et al., 2005).
Incretin action and the treatment of type 2 diabetes
Continuous administration of GLP-1 lowers blood glucose to
near normal levels in both the fasting and postprandial state inCELL METABOLISM : MARCH 2006diabetic human subjects via inhibition of gastric emptying and
glucagon secretion, and stimulation of insulin secretion (Rach-
man et al., 1997; Toft-Nielsen et al., 1999). The importance of
basal levels of GLP-1R signaling for control of glycemia indepen-
dent of meals is illustrated by studies demonstrating that contin-
uousGLP-1 infusion frommidnight to 8 AM significantly reduced
glucose concentrations during the overnight period in subjects
with type 2 diabetes (Rachman et al., 1997). The actions of
GLP-1 on gastric emptying in human subjects are sufficiently po-
tent soas tomarkedly attenuatemeal-relatedglucoseexcursion,
thereby potentially reducing insulin secretion from the pancre-
atic b cell, depending on the level of ambient glucose excursion
achieved following GLP-1 administration (Nauck et al., 1997;
Todd et al., 1997). Consistent with the importance of glucagon
suppression and gastric emptying for GLP-1 action, short-term
studies demonstrate that GLP-1 significantly lowers blood glu-
cose in subjectswith type 1 diabetes (Dupre et al., 1995; Gutniak
et al., 1992).
Proof of concept for the feasibility of using native GLP-1 for
therapeutic purposeswas obtained in a 6 week study of patients
with type 2diabetes.GLP-1delivered via continuous subcutane-
ous infusion significantly lowered both fasting and postprandial
glucose, in association with a 1.3% reduction in HbA1c (Zander
et al., 2002). GLP-1 therapy was well tolerated, and associated
with reduced levels of free fatty acids, improved insulin sensitiv-
ity, and a 1.9 kg reduction in bodyweight (Zander et al., 2002). As
the native GLP-1 peptide undergoes rapid enzymatic inactiva-
tion by DPP-4, the efficacy of degradation resistant GLP-1R ag-
onists suitable for once or twice daily administration has been
examined (Table 1).
Exendin-4 is a naturally occurring 39 amino acid GLP-1 recep-
tor agonist originally isolated from the venom of the Heloderma
suspectum lizard (Eng et al., 1992). Exendin-4 is encoded by
a distinct gene in the lizard, which also contains 2 genes for pro-
glucagon (Chen and Drucker, 1997), however a gene for exen-
din-4 has not yet been detected in mammalian species. Align-
ment of native GLP-1 and exendin-4 amino acid sequences
demonstrates 53%amino acid identity, and exendin-4 is a highly
potent GLP-1R agonist both in vitro and in vivo. Exendin-4 con-
tains a glycine residue at position 2, thereby conferring resis-
tance to cleavage by DPP-4.
Exendin-4 mimics all of the glucose-lowering actions of GLP-
1, yet is several orders of magnitude more potent than native
GLP-1 following parenteral administration, due to its enhanced
pharmacokinetic profile (Young et al., 1999). Twice-daily admin-
istration of three different doses of exendin-4 to patients with
type 2 diabetes receiving one or two oral antidiabetic agents
demonstrated significant lowering of blood glucose and a reduc-
tion of HbA1c of 0.7%–1.1% over a 28 day treatment period
(Fineman et al., 2003). Phase 3 clinical trials assessed the effi-
cacy of exendin-4, 5 or 10 mg twice daily, added to patients not
achieving optimal glucose control with either metformin, a sulfo-
nylurea, or both, for 30 weeks. Exendin-4 (exenatide) was effec-
tive in lowering HbA1c in all 3 treatment groups by about 0.9%,
with nausea the principal side effect noted in all three studies
(Buseet al., 2004;DeFronzoet al., 2005;Kendall et al., 2005). Ap-
proximately 34%–46% of patients achieved a HbA1c less than
7% after addition of exenatide (Buse et al., 2004; DeFronzo
et al., 2005; Kendall et al., 2005). Patients receiving concomitant
sulfonylurea therapy experienced an increased rate of mild to
moderate hypoglycemia, however exendin-4 therapy was159
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groups (Buse et al., 2004; DeFronzo et al., 2005; Kendall et al.,
2005). Although anti-exendin-4 antibodies were detected in
41%–49% of treated patients after 30 weeks (Buse et al.,
2004; DeFronzo et al., 2005; Kendall et al., 2005), the presence
or absence of antibodies did not correlate with the therapeutic
response in exendin-4-treated subjects (Buse et al., 2004;
DeFronzo et al., 2005; Kendall et al., 2005).
Exenatide has also been comparedwith insulin glargine as ad-
junctive therapy for patients with type 2 diabetes not optimally
controlled on oral agents with a mean initial starting HbA1c of
8.2%–8.3%. Exenatide and insulin glargine produced compara-
ble reductions in HbA1c (w1.1%) over a 26 week treatment
period (Heine et al., 2005). Exenatide produced a greater reduc-
tion in postpranial glucose whereas insulin glargine was more
effective at lowering fasting glucose. The incidence of gastroin-
testinal side effects, including nausea, vomiting, and diarrhea,
was significantly greater in patients treatedwith Exenatide, how-
ever Exenatide therapy was associated with a mean 2.3 kg
weight loss,whereaspatients treatedwith insulin glarginegained
w1.8 kg (Heine et al., 2005).
Complementary approaches for development ofGLP-1Rago-
nists include the generation of longer-acting DPP-4-resistant
GLP-1 analogs. Liraglutide (NN2211) is a fatty acylated GLP-1
molecule that exhibits a prolonged pharmacokinetic profile after
a single injection due to noncovalent association with albumin
(Juhl et al., 2002). Liraglutide mimics all of the actions of native
GLP-1 and effectively lowers blood glucose in human subjects
with type 2 diabetes (Madsbad et al., 2004). The long circulating
t1/2 of albumin, w11 days in human subjects, has fostered the
development of CJC-1131 and Albugon, albumin-linked GLP-
1R agonists with more prolonged durations of action in vivo
(Baggio et al., 2004; Kim et al., 2003). Furthermore, a long-acting
version of exendin-4 (Exenatide-LAR) developed using a poly-
lactide-glycolide microsphere suspension appears to control
glucose for weeks after a single injection in diabetic rats (Gedulin
et al., 2005) and is being evaluated in Phase 2 clinical trials in
human subjects with type 2 diabetes.
Dipeptidyl Peptidase-4
A complementary approach for enhancing the action of GLP-1
and GIP involves inhibiting the action of CD26, also known as
DPP-4, the key enzyme responsible for cleaving and inactivating
both of these 2peptides at thepenultimate alanine residue (Men-
tlein et al., 1993). DPP-4 is a complex, widely expressed enzyme
that exists in 2 principal forms; a membrane anchored, largely
extracellular protein capable of stimulation of intracellular signal
Table 1. Properties of GLP-1R agonists versus DPP-4 inhibitors for the treatment
of type 2 diabetes
GLP-1R Agonists DPP-4 Inhibitors
Injectable Orally available
May produce nausea and vomiting Well tolerated
Satiety and weight loss Weight neutral
GLP-1 receptor-dependent MOA GLP-1 and GIP
receptor-dependent MOA
Pharmacological GLP-1R potentiation Enhancement of endogenous
incretin action
MOA = mechanism of action.160transduction pathways independent of its enzymatic activity,
and a circulating soluble enzyme which retains enzymatic activ-
ity. The biological importance of DPP-4 has been examined in
animals following administration of both selective and nonselec-
tive DPP-4 inhibitors, and in rats and mice with inactivating
DPP-4 mutations. Fischer 344/CRJ rats with a spontaneous in-
activating DPP-4 mutation exhibit reduced numbers of CD4(+)
T lymphocytes in response to ovalbumin immunization, in asso-
ciation with significantly reduced ovalbumin-specific IgE-titres
(Kruschinski et al., 2005). Similarly, CD26 knockout mice exhibit
an altered distribution of splenic T lymphocytes and a reduced
level of circulating CD4(+) NKT lymphocytes (Yan et al., 2003).
Furthermore, serum levels of total IgG, IgG1, IgG2a, and IgE
were lower in sera of CD262/2 mice following immunization
with pokeweedmitogen, in association with reduced generation
of IL-4 and IL-2 and delayed IFN-g production (Yan et al., 2003).
Moreover, CD262/2 mice exhibit defects in nociception (Guieu
et al., 2005) and enhanced severity of experimental arthritis
(Busso et al., 2005). Whether highly specific submaximal inhibi-
tion of only the catalytic activity of DPP-4 will be associated
with similar phenotypes in human subjects chronically treated
with DPP-4 inhibitors is not known.
Genetic evidence supports an essential role for DPP-4 in the
control of glucose homeostasis. Fischer 344/CRJ rats exhibit in-
creased levels of GLP-1 and reduced glycemic excursion follow-
ing glucose challenge (Nagakura et al., 2001). Similarly, mice
with a targeted inactivation of the DPP-4 gene exhibit improved
glucose tolerance, enhanced levels of GLP-1, GIP, and insulin,
improved insulin sensitivity, and resistance to diet-induced obe-
sity (Conarello et al., 2003;Marguet et al., 2000). Similarly, chem-
ical inhibitors of DPP-4 prevent the inactivation of both GLP-1
and GIP and lower blood glucose in both preclinical (Deacon,
2004, 1998) and human studies (Ahren et al., 2004a, 2002). Inhi-
bitionofDPP-4activity in 4–52week studies reduces the levels of
HbA1c, in association with prevention of weight gain, potentia-
tion of b cell function, and suppression of plasma glucagon in
human subjects with type 2 diabetes (Ahren et al., 2004a,
2004b, 2005).
Numerous peptides and chemokines contain an alanine or
proline at position 2 and are susceptible to cleavage by DPP-4,
hence the precise identity of the peptide substrates thatmediate
the glucose-lowering actions of DPP-4 inhibitors remains un-
clear.DPP-4 inhibitors completely lose their ability to lowerblood
glucose in mice with genetic disruption of both GLP-1 and GIP
receptors (Hansotia et al., 2004). The results of experiments us-
ing nonselective versus highly selective DPP-4 inhibitors sug-
gests that DPP-4-selective inhibitors are comparatively safe
when administered in high doses to mice, rats, and dogs and
do not inhibit human T cell activation in vitro (Lankas et al.,
2005). Whether long term selective inhibition of DPP-4 activity
in human subjects will significantly perturb the biological activity
of peptides such as pituitary adenylate cyclase-activating poly-
peptide (Zhu et al., 2003), stromal cell-derived factor-1 (SDF-1)
(Busso et al., 2005), or substance P (Guieu et al., 2005) remains
unknown.
Conclusion
Our understanding of incretin biology has expanded exponen-
tially over the past two decades. Both GLP-1 and GIP exert ac-
tions well beyond the b cell, and the roles of these peptides inCELL METABOLISM : MARCH 2006
R E V I E Wperipheral organssuchasadipose tissue, thebrain, and theheart
are receiving increasing attention. Our knowledge of incretin
biology remains incomplete, andadditional studies on themech-
anism of action of both GIP andGLP-1 arewarranted. For exam-
ple, what are the effects of GIPR agonists or DPP-4 inhibitors in
adipose tissue, and is it beneficial or deleterious to antagonize
GIP action in type 2 diabetes? Why does the human diabetic
b cell lose responsivity to GIP but not to GLP-1? What are the
consequences of inhibiting DPP-4 on peptide substrates not re-
lated to control of glucose homeostasis? Furthermore, the
emerging clinical use of strategies based on enhancement of
incretin action (GLP-1R agonists and DPP-4 inhibitors) raises
additional questions related to mechanisms of action in human
subjects. For example, can GLP-1R agonists be used safely
without engendering immune responses in a subset of treated
individuals? Is there a potential for the proliferative and antiapo-
ptotic actions of GLP-1R agonists to prevent the decline in b cell
mass and function characteristic of the natural history of type 2
diabetes? Similarly, will therapy with GLP-1R agonists or DPP-4
inhibitors (Table 1) prove any more durable and control HbA1c
better for longer periods of time than currently available agents?
Conversely, is there a risk that prolongedGLP-1 receptor activa-
tion will lead to uncontrolled cell proliferation and potentially C
cell hyperplasia in the thyroid or nesidioblastosis and the devel-
opment of pancreatic endocrine tumors? Taken together, the
potential promise of incretin therapy for the treatment of type 2
diabetes suggests a detailed understanding of incretin biology
in multiple systems appears warranted.
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